Ipsen SA EURONEXT:IPN:
TO BUY KARTOS THERAPEUTICS IN DEFINITIVE MERGER AGREEMENT
IPSEN TO ACQUIRE KARTOS THERAPEUTICS, EXPANDING HEMATO-ONCOLOGY LATE-STAGE PIPE
TO PAY $450 MILLION UPFRONT FOR KARTOS THERAPEUTICS ACQUISITION
DEAL EXPECTED TO CLOSE BY END OF Q3 2026
DEAL EXPECTED TO BE ACCRETIVE TO IPSEN CORE OPERATING INCOME FROM 2029
TOP-LINE DATA FROM PHASE III POIESIS TRIAL EXPECTED IN 2027
KARTOS SHAREHOLDERS ELIGIBLE FOR UP TO $1.3 BILLION IN MILESTONE PAYMENTS
ACQUISITION ADDS PHASE III NAVTEMADLIN TO IPSEN ONCOLOGY PORTFOLIO